Scientists test common Antibiotic's impact on experimental cancer treatment
NCT ID NCT00750841
Summary
This study aims to understand how the antibiotic rifampicin affects the way the body processes an experimental cancer drug called cediranib. It involves 64 patients with advanced solid tumors that have not responded to standard treatments. The main goal is to measure drug levels in the blood to see if the antibiotic changes them, which helps determine safe dosing for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
Conditions
Explore the condition pages connected to this study.